The authors reported that MCC950 treatment improved diabetes-induced kidney injury on multiple parameters including serum creatinine, urinary albumin excretion, mesangial expansion and the renal gene and protein expression of mediators of kidney injury including TGF-β, collagen 1, fibronectin and α-SMA. This evidence concerns the gene ALB and diabetes mellitus.